Non-18F-FDG PET/CT in the management of patients affected by HNC: state-of-the-art. Issue 9 (September 2016)

• Record Type: Journal Article
• Authors: Quartuccio, Natale; Caobelli, Federico; Di Mauro, Francesca; Cammaroto, Giovanni
• Is Part Of: Nuclear medicine communications. Volume 37:Issue 9(2016:Sep.)
• Publication Date: 2016-09
• Subjects: fluorohymidine -- head and neck cancer -- hypoxia imaging -- methionine -- non-18F-FDG PET/CT -- PET -- somatostatin receptor imaging; Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000000530
• Languages: English
• ISSNs: 0143-3636

Abstract

Abstract : PET/computed tomography with 18 F-fluorodeoxyglucose is considered a powerful molecular imaging technique that can provide useful information in the management of patients affected by head and neck cancer. However, misleading findings have been reported because of nonspecific uptake caused by peritumoural inflammation and physiologic changes in nonmalignant tissues in the head and neck region. More specific β-emitting tracers have been introduced that can track other pathological processes. We aimed to review the existing literature performing the search until June 2015 on non- 18 F-fluorodeoxyglucose PET tracers in head and neck cancer to highlight their role in clinical practice.